PersonScientistExecutive
Lisa Olson
Lisa M. Olson, Ph.D., is a biopharmaceutical research leader who became CEO of Milan-based clinical-stage biotech Enthera Pharmaceuticals in January 2024, after years on its board and as chair of its Scientific Advisory Board. Across two decades in immunology drug discovery - 15 years at AbbVie/Abbott where she helped advance 15 molecules into the clinic including Rinvoq, plus roles at Pfizer and as Chief Scientific Officer of Magenta Therapeutics - she has built a career turning biology into medicine. At Enthera she is steering the clinical development of Ent001, a first-in-class antibody targeting the IGFBP3/TMEM219 pathway for inflammatory bowel disease and type 1 diabetes.
lisa olsonlisa m. olsonenthera pharmaceuticalsceobiotechimmunology
